AZU1 and breast carcinoma: With regard to the effects of PDIA3 inhibition on promigratory phenotypes of breast cancer cells (23) and in consideration of PDIA3 as a prospective therapeutic target in breast cancer, we report here a comparative proteomic analysis to identify effects of 16F16 inhibition on the secreted, heparin-binding proteins produced by MDA-MB-231 cells.